Corient Private Wealth’s BioMarin Pharmaceuticals BMRN Stock Holding History

Corient Private Wealth’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.03M	Buy	35,525 +29,452	+485%	+$1.61M	﹤0.01%	1387
2026 Q1	$337K	Buy	6,073 +2,391	+65%	+$139K	﹤0.01%	2256
2025 Q4	$218K	Sell	3,682 -2,154	-37%	-$117K	﹤0.01%	2376
2025 Q3	$316K	Sell	5,836 -514	-8%	-$29.4K	﹤0.01%	2083
2025 Q2	$349K	Buy	6,350 +1,616	+34%	+$95.2K	﹤0.01%	1905
2025 Q1	$335K	Buy	+4,734	New	+$318K	﹤0.01%	1801
2024 Q3	–	Sell	-4,286	Closed	-$353K	–	2477
2024 Q2	$353K	Sell	4,286 -322	-7%	-$26.8K	﹤0.01%	1817
2024 Q1	$402K	Buy	4,608 +109	+2%	+$9.76K	﹤0.01%	1741
2023 Q4	$434K	Buy	4,499 +429	+11%	+$38K	﹤0.01%	1682
2023 Q3	$361K	Sell	4,070 -29	-0.7%	-$2.58K	﹤0.01%	1655
2023 Q2	$355K	Buy	4,099 +172	+4%	+$16.2K	﹤0.01%	1622
2023 Q1	$382K	Sell	3,927 -28	-0.7%	-$2.9K	﹤0.01%	1488
2022 Q4	$409K	Buy	+3,955	New	+$371K	﹤0.01%	1214

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Corient Private Wealth's BMRN Position: Q2 2026 in Review

Corient Private Wealth increased its BioMarin Pharmaceuticals (BMRN) stake by 485% in Q2 2026, buying an estimated $1.61M and bringing the position to 35,525 shares worth $2.03M. The position accounts for ﹤0.01% of the portfolio, ranked #1387.

Corient Private Wealth first reported a position in BMRN in Q4 2022 and has held it in 13 quarters since. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Corient Private Wealth held 35,525 shares of BioMarin Pharmaceuticals worth $2.03M as of Q2 2026.
Corient Private Wealth bought 29,452 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $1.61M.
BioMarin Pharmaceuticals made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #1387 holding.
Corient Private Wealth first reported a position in BioMarin Pharmaceuticals in Q4 2022 and has held it in 13 quarters since.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.